Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

NCT03277690 is registered in ClinicalTrials.gov with Cortendo AB as lead sponsor.

NCT NCT03277690
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03277690 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
Lead sponsor
Cortendo AB
Phase
Phase 3
Overall status
Completed
Start date
September 26, 2017
Completion date
August 31, 2020
Enrollment
84 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

endogenous cushing's syndrome